Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity

Karsenty, G.; Reitz, André; Lindemann, Gertraud; Boy, Sönke; Schurch, Brigitte

doi:10.1016/j.urology.2006.08.1069

Cited by 96 publications

(51 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of the previous open-label studies confirmed the positive impact of BoNT-A on the decrease of Pdet.Qmax in NDO. 4,[10][11][12] The mean percentage reduction in Pdet.Qmax from baseline was approximately from 40 to 60%, and in most of these studies, the mean Pdet.Qmax was reduced to less than 40 cm H 2 O after BoNT-A treatment, which is generally considered as the desired Pdet.Qmax for upper urinary tract protection. 13 We found a positive impact of BoNT-A on Pdet.Qamx reduction in this study (40.7±21.3 vs 26.1 ± 17.2 cm H 2 O, P ¼ 0.01).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia

Kuo

2011

Spinal Cord

View full text Add to dashboard Cite

Study design: The study was designed as a single-arm clinical trial. Objectives: To investigate the therapeutic effects of detrusor botulinum toxin A (BoNT-A) treatment in patients with different levels of spinal cord injury (SCI) and types of detrusor sphincter dyssynergia (DSD). Setting: Patients with chronic suprasacral SCI and neurogenic detrusor overactivity (NDO) were treated with 200-U BoNT-A detrusor injection in a tertiary university hospital in Taiwan. Methods: Outcome assessment of urodynamic parameters and therapeutic satisfaction were performed at 3 and 6 months among patients with different demographics, SCI levels and types of DSD. The treatment outcomes were assessed by changes in Urogenital Distress Inventory 6-item short form (UDI-6), quality of life (QoL) index and detrusor pressure at maximum flow rate (Pdet.Qmax). Results: A total of 38 patients with a mean age of 40.1±12.4 years and median duration of SCI of 10.3 years were enrolled. Satisfactory response was reported in 23 (60%) patients. Significant improvements in the UDI-6 and QoL were reported and significant increases of cystometric bladder capacity and post-void residual were noted in overall patients after treatment. Patients with different clinical demographics and urodynamic parameters had similar treatment outcomes and UDI-6 scores. In 11 patients receiving repeat injections of 300 U of BoNT-A after failure of a previous 200 U injection, the treatment outcomes were not significantly different, except that the PdetQmax at 6 months were higher in the group that received 200 U of BoNT-A. Conclusion: Patients with different SCI levels or DSD types had similar treatment outcomes after detrusor 200 U BoNT-A injections for NDO.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia

Kuo

2011

Spinal Cord

View full text Add to dashboard Cite

show abstract

“…After a rapid onset of effect (Kalsi et al, 2008), the mean duration of efficacy in single-injection studies was 8 months (range: 12-36 wk). Repeated treatments showed sustained clinical benefits in open-label studies using up to five injections of Botox or seven injections of Dysport (Del Popolo et al, 2008;Grosse et al, 2005;Karsenty et al, 2006, Reitz et al, 2007.…”

Section: Botulinum a Toxin As Second Line Treatment For Refractory Dementioning

confidence: 99%

Botulinum A Toxin Intravesical Injections in the Treatment of Refractory Overactive Bladder in Patients with Parkinson's Disease

Giannantoni¹,

Proietti²,

Conte³

et al. 2011

Towards New Therapies for Parkinson's Disease

View full text Add to dashboard Cite

“…BoNT enjeksiyonundan sonra tedavi etkinli¤inin ne kadar devam etti¤i de araflt›r›lm›flt›r. Karsenty ve arkadafllar› (21) retrospektif olarak en az 3 kez BoNT uygulanan 17 hastay› araflt›rm›fllard›r. BoNT enjeksiyonlar› aras›ndaki zaman›n 7.6 ile 9.1 ay aras›nda de¤iflti¤ini belirtmifllerdir.…”

Section: Botul‹nyum Toks‹n‹ Enjeks‹yonuunclassified

Botulinum toxin and neuromodulation for overactive bladder treatment

Akman¹

2013

J Turk Soc Obstet Gynecol

View full text Add to dashboard Cite

show abstract

Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity

Cited by 96 publications

References 22 publications

Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia

Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia

Botulinum A Toxin Intravesical Injections in the Treatment of Refractory Overactive Bladder in Patients with Parkinson's Disease

Botulinum toxin and neuromodulation for overactive bladder treatment

Contact Info

Product

Resources

About